JN
$259.55
+4.77
(+1.87%)
As of Oct 7, 2026, 2:43 PM EDT
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Jul 17, 2026, the first target we tracked for JNJ.
Johnson & Johnson (JNJ) is trading up at $259.55 (+1.87%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on JNJ
Current price targets from 5 firms average $280, median $280, ranging from $270 to $290 — the average is 8% above the current $260. Each is tracked to its date and scored the same way a member's call is.
- RBC Capital Markets $255 → $290 by Oct 2027 Oct 6, 2026 via Investing.com · RBC Capital Markets's track record
- Bank of America $265 → $278 by Sep 2027 Sep 30, 2026 via AOL.com · Bank of America's track record
- Raymond James $254 → $280 by Aug 2027 Aug 3, 2026 via Investing.com · Raymond James's track record
- Wells Fargo $254 → $282 by Aug 2027 Aug 3, 2026 via GuruFocus · Wells Fargo's track record
- Guggenheim $253 → $270 by Jul 2027 Jul 17, 2026 via MarketBeat · Guggenheim's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Johnson & Johnson revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Jan 2017 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Jan 2021 | FY2021Jan 2022 | FY2022Jan 2023 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $71.9B | $76.5B | $81.6B | $82.1B | $82.6B | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Growth (year over year) | +2.6% | +6.3% | +6.7% | +0.6% | +0.6% | −4.7% | +1.6% | +6.5% | +4.3% | +6.0% |
| Gross profit | $50.1B | $51.0B | $54.5B | $54.5B | $54.2B | $55.3B | $55.4B | $58.6B | $61.4B | $63.9B |
| Gross margin | 69.7% | 66.7% | 66.8% | 66.4% | 65.6% | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Net income | $16.5B | $1.30B | $15.3B | $15.1B | $14.7B | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Net margin | 23.0% | 1.7% | 18.8% | 18.4% | 17.8% | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| EPS (diluted) | $5.93 | $0.47 | $5.61 | $5.63 | $5.51 | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Balance sheet | ||||||||||
| Cash and equivalents | $19.0B | $17.8B | $18.1B | $17.3B | $14.0B | $14.5B | $12.9B | $21.9B | $24.1B | $19.7B |
| Total assets | $141.2B | $157.3B | $153.0B | $157.7B | $174.9B | $182.0B | $187.4B | $167.6B | $180.1B | $199.2B |
| Total liabilities | $70.8B | $97.1B | $93.2B | $98.3B | $111.6B | $108.0B | $110.6B | $98.8B | $108.6B | $117.7B |
| Long-term debt | $22.4B | $30.7B | $27.7B | $26.5B | $32.6B | $30.0B | $26.9B | $25.9B | $30.7B | $39.4B |
| Shareholders' equity | $70.4B | $60.2B | $59.8B | $59.5B | $63.3B | $74.0B | $76.8B | $68.8B | $71.5B | $81.5B |
| Cash flow | ||||||||||
| Operating cash flow | $18.8B | $21.1B | $22.2B | $23.4B | $23.5B | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| Capital expenditure | $3.23B | $3.28B | $3.67B | $3.50B | $3.35B | $3.65B | $4.01B | $4.54B | $4.42B | $4.83B |
| Free cash flow | $15.5B | $17.8B | $18.5B | $19.9B | $20.2B | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| Share buybacks | $8.98B | $6.36B | $5.87B | $6.75B | $3.22B | $3.46B | $6.04B | $5.05B | $2.43B | $5.95B |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $22.5B | $22.5B | $21.9B | $23.7B | $24.0B | $24.6B | $24.1B | $25.3B |
| Growth (year over year) | +5.2% | +5.3% | +2.4% | +5.8% | +6.8% | +9.1% | +9.9% | +6.6% |
| Gross profit | $15.5B | $15.4B | $14.5B | $16.1B | $16.7B | $16.6B | $16.0B | $17.3B |
| Gross margin | 69.0% | 68.3% | 66.4% | 67.9% | 69.6% | 67.6% | 66.3% | 68.2% |
| Net income | $2.69B | $3.43B | $11.0B | $5.54B | $5.15B | $5.12B | $5.24B | $5.53B |
| Net margin | 12.0% | 15.2% | 50.2% | 23.3% | 21.5% | 20.8% | 21.8% | 21.9% |
| EPS (diluted) | $1.11 | $1.41 | $4.54 | $2.29 | $2.12 | $2.08 | $2.14 | $2.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $20.0B | $24.1B | $38.5B | $18.6B | $18.2B | $19.7B | $21.7B | $20.4B |
| Total assets | $178.3B | $180.1B | $193.7B | $193.4B | $192.8B | $199.2B | $200.9B | $201.1B |
| Total liabilities | $108.1B | $108.6B | $115.6B | $114.9B | $113.5B | $117.7B | $119.7B | $116.1B |
| Long-term debt | $31.3B | $30.7B | $38.4B | $39.2B | $39.4B | $39.4B | $37.5B | $37.3B |
| Shareholders' equity | $70.2B | $71.5B | $78.1B | $78.5B | $79.3B | $81.5B | $81.2B | $85.0B |
| Cash flow | ||||||||
| Operating cash flow | $7.99B | $6.98B | $4.17B | $3.88B | $9.17B | $7.31B | $2.51B | $8.62B |
| Capital expenditure | $1.03B | $1.61B | $795.0M | $1.04B | $1.16B | $1.84B | $1.05B | $1.32B |
| Free cash flow | $6.96B | $5.37B | $3.38B | $2.83B | $8.01B | $5.47B | $1.47B | $7.29B |
| Share buybacks | $539.0M | $282.0M | $2.13B | $0 | $1.90B | $1.92B | $4.03B | $221.0M |
From Johnson & Johnson's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Johnson & Johnson
- Headquarters
- New Brunswick, New Jersey From SEC filings, Oct 2026
Recent News (20)
-
Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock (JNJ)? Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock (JNJ)? Simply Wall Street
-
Johnson & Johnson (JNJ): RBC Update & Stock Analysis Johnson & Johnson (JNJ): RBC Update & Stock Analysis The Globe and Mail
-
ETFs Sold $69.4 Million of Johnson & Johnson (JNJ) on Oct. 5 ETFs Sold $69.4 Million of Johnson & Johnson (JNJ) on Oct. 5 GuruFocus
-
-
JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation Stocktwits
-
-
-
-
-
-
-
-
-
JNJ Dec 2028 165.000 put (JNJ281215P00165000) interactive stock chart JNJ Dec 2028 165.000 put (JNJ281215P00165000) interactive stock chart Yahoo Finance UK
-
-
-
-
-
-
More Health Care stocks
- ILMN Illumina
- INCY Incyte
- IQV IQVIA
- ISRG Intuitive Surgical
- LH Labcorp
- LLY Lilly (Eli)
- MCK McKesson Corporation
- MDT Medtronic